Restless Legs Syndrome Market

By Type;

Primary Restless Legs Syndrome and Secondary Restless Legs Syndrome

By Route of Administration;

Oral and Injectable

By Treatment Type;

Medication & Devices, Dopamine Agonists, Anti-Seizure Agent, Benzodiazepines, Opioids, and Others

By Distribution Channel;

Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn154741157 Published Date: June, 2025 Updated Date: July, 2025

Introduction

Global Restless Legs Syndrome Market (USD Million), 2021 - 2031

In the year 2024, the Global Restless Legs Syndrome Market was valued at USD 2193.81 million. The size of this market is expected to increase to USD 3086.91 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.0%.


Restless Legs Syndrome Market

*Market size in USD million

CAGR 5.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)5.0 %
Market Size (2024)USD 2193.81 Million
Market Size (2031)USD 3086.91 Million
Market ConcentrationMedium
Report Pages343
2193.81
2024
3086.91
2031

Major Players

  • GlaxoSmithKline plc
  • UCB S.A.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Jazz Pharmaceuticals plc
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Restless Legs Syndrome Market

Fragmented - Highly competitive market without dominant players


Restless Legs Syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move the legs, often accompanied by uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, such as when sitting or lying down, and can severely disrupt sleep patterns. RLS affects millions of people worldwide, with prevalence rates varying across different populations and demographics. Although the exact cause of RLS remains unknown, factors such as genetics, dopamine dysfunction, iron deficiency, and certain medical conditions are believed to play a role in its development.

The global market for Restless Legs Syndrome treatments has witnessed significant growth in recent years, driven by a rising awareness of the condition and advancements in medical research. Pharmaceutical companies are actively engaged in developing novel therapies aimed at alleviating the symptoms of RLS and improving patients' quality of life. These treatments range from dopaminergic agents and opioids to iron supplements and lifestyle modifications. Additionally, non-pharmacological approaches such as exercise, massage, and behavioral therapy are gaining traction as complementary strategies for managing RLS symptoms.

The growing market for RLS treatments, challenges persist in accurately diagnosing the condition and tailoring therapies to individual patient needs. Furthermore, access to effective treatments remains a concern in many regions, particularly in low- and middle-income countries where healthcare infrastructure may be limited. Addressing these challenges requires collaborative efforts among healthcare professionals, researchers, policymakers, and industry stakeholders to enhance RLS awareness, improve diagnostic capabilities, and ensure equitable access to care for all individuals affected by this debilitating disorder.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Route of Administration
    3. Market Snapshot, By Treatment Type
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. Restless Legs Syndrome Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Advancements in medical research and technology
        2. Increasing awareness and diagnosis of restless legs syndrome
      2. Restraints
        1. Side effects associated with current treatments
        2. Limited understanding of the underlying causes of restless legs syndrome
      3. Opportunities
        1. Development of novel therapeutics and treatment options
        2. Growing demand for effective management of restless legs syndrome symptoms
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Restless Legs Syndrome Market, By Type, 2021 - 2031 (USD Million)
      1. Primary Restless Legs Syndrome
      2. Secondary Restless Legs Syndrome
    2. Restless Legs Syndrome Market, By Route of Administration, 2021 - 2031 (USD Million)
      1. Oral
      2. Injectable
    3. Restless Legs Syndrome Market, By Treatment Type, 2021 - 2031 (USD Million)
      1. Medication & Devices
      2. Dopamine Agonists
      3. Anti-Seizure Agent
      4. Benzodiazepines
      5. Opioids
      6. Others
    4. Restless Legs Syndrome Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    5. Restless Legs Syndrome Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. GlaxoSmithKline plc
      2. UCB S.A.
      3. Pfizer Inc.
      4. Merck & Co., Inc.
      5. Boehringer Ingelheim International GmbH
      6. Sanofi S.A.
      7. Teva Pharmaceutical Industries Ltd.
      8. Jazz Pharmaceuticals plc
      9. Sun Pharmaceutical Industries Ltd.
      10. Mylan N.V.
  7. Analyst Views
  8. Future Outlook of the Market